Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

BACKGROUND: Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin’s lymphoma. Bortezomib is the first product to be approved for the treatment of patients with previously untreated MCL, for whom haematopoietic stem cell transplantation is unsuitable, and is used in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: van Keep, Marjolijn, Gairy, Kerry, Seshagiri, Divyagiri, Thilakarathne, Pushpike, Lee, Dawn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972997/
https://www.ncbi.nlm.nih.gov/pubmed/27488675
http://dx.doi.org/10.1186/s12885-016-2633-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972997/
https://www.ncbi.nlm.nih.gov/pubmed/27488675
http://dx.doi.org/10.1186/s12885-016-2633-2

Ejemplares similares